ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for ...

FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved ...

The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.

An investigator behind gedatolisib's FDA approval discusses the trial data, dosing, and adverse effects shaping HR+/HER2- ...

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

Community oncology improves hereditary cancer care by expanding risk assessment, dense-breast and polyp screening, plus ...

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent ...

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 in favor of the IGNYTE study (NCT03767348) supporting the potential accelerated approval of vusolimogene oderparepvec (RP1; ...

As administrators, physicians, and researchers at cancer centers, we are well aware of the significant impact that the COVID-19 pandemic is having on cancer care worldwide. We are dealing with what I ...

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...